Literature DB >> 2521810

Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase.

R G Morgan1.   

Abstract

Exposure of tumor cells to reduced folates before or with the fluoropyrimidines, 5-fluorouracil or 5-fluoro-2'deoxyuridine, results in a substantial increase in the activity of these drugs. Available evidence suggests that the mechanism of this synergism is a kinetic stabilization of complex formed between thymidylate synthase and fluorodeoxyuridylate that also involves a mole of the cofactor for the thymidylate synthase reaction, 5,10-methylenetetrahydrofolate. This effect results in an extended time of depletion of thymidine nucleotides with a resultant increased level of cell death. The biochemical aspects of this interaction are discussed and related to the therapeutics of this combination.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521810     DOI: 10.1002/1097-0142(19890315)63:6+<1008::aid-cncr2820631303>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer.

Authors:  J Clark; W Sikov; F Cummings; M Browne; W Akerley; H Wanebo; A Weitberg; T Kennedy; B Cole; J Bigley; J Beitz; J Darnowski
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin.

Authors:  A Cassano; C Pozzo; D C Corsi; T Fontana; M R Noviello; A Astone; C Barone
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

3.  Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.

Authors:  R M Mader; G G Steger; B Rizovski; A E Sieder; G Locker; M F Gnant; R Jakesz; H Rainer
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

4.  Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.

Authors:  T L Chen; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid.

Authors:  J L Fischel; P Formento; M Berlion; J Berille; J Gioanni; J P Bizzari; G Milano
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. A phase I study.

Authors:  D J Schifeling; A A Konski; J M Howard; R R Dobelbower; H W Merrick; R T Skeel
Journal:  Int J Pancreatol       Date:  1992-12

7.  5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. GLISP (Gruppo Ligure Studio Pancreas).

Authors:  E Bolli; S Saccomanno; G Mondini; C Aschele; A Guglielmi; B Ligas; M Connio; A Mori; R Rosso; A Sobrero
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.

Authors:  J H Sips; O van Tellingen; W J Nooijen; S Rodenhuis; W J Ten Bokkel Huinink; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Biomodulation of 5-Fu cytotoxicity by folinic acid and its stereoisomers: in vitro experiments with different cell lines of prostatic cancer.

Authors:  J Breul; G Jakse; R Hartung
Journal:  Urol Res       Date:  1995

10.  Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.

Authors:  Sotaro Sadahiro; T Suzuki; A Tanaka; K Okada; G Saito; H Miyakita; T Ogimi; H Nagase
Journal:  Cancer Chemother Pharmacol       Date:  2017-04-17       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.